drugset / Trial / NCT04592159

Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder

NCT04592159

Phase 2/3 Withdrawn Jazz Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will be conducted to evaluate the efficacy of nabiximols for the treatment of symptoms of post-traumatic stress disorder (PTSD) in participants receiving selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) pharmacotherapy.

Timeline

Start
2021-02-01
Primary completion
2023-03
Completion
2023-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Nabiximols Other / unclassified 0.1 ml Other